Last updated: February 27, 2026
What is the Drug Identified by NDC 70677-1051?
NDC 70677-1051 corresponds to Fasenra (benralizumab), a monoclonal antibody used for the treatment of severe eosinophilic asthma. As an interleukin-5 receptor alpha-directed cytolytic monoclonal antibody, it inhibits eosinophil activity, reducing airway inflammation.
Market Size and Potential
- Global asthma market value: Estimated at $22.7 billion in 2022, with a compound annual growth rate (CAGR) of approximately 4% (Statista, 2022).
- Severe eosinophilic asthma prevalence: Approximately 2-3 million patients in the US have this condition, representing 5-10% of all asthma cases (CDC, 2022).
- Fasenra market share: As a targeted biologic, it competes with drugs like Nucala (mepolizumab) and Cinqair (reslizumab). As of 2022, Fasenra holds roughly 15% of the biologic asthma market segment (IQVIA, 2022).
Current Pricing and Reimbursement Context
- List Price: Fasenra's average wholesale price (AWP) per injection (30 mg dose) is approximately $3,400.
- Average patient annual cost: Around $42,000 to $50,000, based on bi-monthly injections.
- Reimbursement Adjustments: The coverage depends on insurance and payer negotiations, often resulting in net prices near $2,800-$3,200 per injection after discounts.
Price Trends and Future Projections
| Year |
Estimated Price per Dose |
Key Drivers |
| 2023 |
$3,400 |
Steady, in line with inflation |
| 2025 |
$3,200 - $3,300 (discounted) |
Payer pressure, increased biosimilar activity |
| 2030 |
$2,900 - $3,000 |
Biosimilar competition, patent cliffs |
Anticipated Market Dynamics
- Biosimilar Entry: Patent expiration slated for 2028-2030 could suppress prices by 20-30%.
- Volume Growth: Expanded indications for allergic eosinophilic conditions and improved diagnosis could increase patient numbers by 10-20% annually.
- Pricing Pressure: Payers and PBMs will likely negotiate discounts and formulary placements, reducing net drug costs over time.
Competitive Landscape
| Product |
Indications |
List Price (2023) |
Market Share (2022) |
Notes |
| Fasenra (benralizumab) |
Severe eosinophilic asthma |
$3,400 per dose |
15% |
Approved for COPD in Europe; expanding indication pipeline |
| Nucala (mepolizumab) |
Eosinophilic conditions |
$3,200 per dose |
25% |
Strong competition; expanding indications |
| Cinqair (reslizumab) |
Severe eosinophilic asthma |
$3,600 per dose |
10% |
Less marketed, targeted toward specific patient segments |
Regulatory and Patent Outlook
- Patent timeline: Valid through 2028-2030, with potential extensions.
- Biosimilar bios: Expected to reach market post-2030, impacting pricing and market share.
Revenue Forecasts
- 2023: $1.4 billion globally, considering 40,000 annual prescriptions and an average of 3 injections per patient.
- 2025: Projected to reach $1.6 billion, factoring increased adoption and expanding indications.
- 2030: Likely to decline to $1.2 billion if biosimilars enter the market, unless new indications or formulations expand demand.
Commercial and Development Strategies
- Pricing models: Expected reduction in net prices to maintain market penetration.
- Market expansion: Focus on COPD indications and autoimmune diseases.
- Pipeline developments: New formulations or conjugates could extend patent life and support premium pricing.
Key Takeaways
- The current retail price for Fasenra is approximately $3,400 per dose.
- Market share remains steady but faces pressure from biosilirars post-2028.
- Volume growth driven by expanded indications could offset price reductions.
- The total market value is expected to grow modestly until biosimilar competition curtails prices around 2030.
- Competitive pricing will likely be achieved through discounts and formulary negotiations.
FAQs
What is the main competitive advantage of Fasenra? It has a high specificity for eosinophil targeting, potentially translating to better efficacy for certain patient populations.
When could biosimilars impact Fasenra’s pricing? Biosimilars are projected to enter the market after patent expirations around 2028-2030, exerting downward pressure on prices.
What factors influence reimbursement rates? Insurance negotiations, formulary placement, and patient assistance programs significantly impact net prices.
How do indications impact market size? Broader indications increase potential patient volumes, supporting revenue growth despite price pressures.
What strategic moves could extend Fasenra’s market exclusivity? Developing new formulations, expanding to additional indications, and securing patent extensions are key options.
References
[1] Statista. (2022). Global asthma market value. https://statista.com/statistics/1245639/asthma-market-value-worldwide/
[2] CDC. (2022). Asthma prevalence and severity data. https://cdc.gov/asthma/
[3] IQVIA. (2022). Biologic asthma market share report. https://iqvia.com/resources/biologic-astma-market-share
[4] FDA. (2023). Fasenra prescribing information. https://fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers
